Reports
RECENT NEWS
Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice
Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta... Read more
FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15
CMPI's Peter Pitts discusses FDA approval of Pfizer COVID vaccine booster for children ages 12-15... Read more
Should We Rethink The FDA Commissionership?
When one considers the FDA’s mission—to independently protect consumers and advance the public health—it is not at all cl... Read more